Moving iMage Q4 Revenue Falls to $4.55M as Net Loss Reaches $296K

Moving iMage Technologies (MITQ) reported Q4 2026 revenue of $4.55M, down from $5.88M a year earlier, with a net loss of $296K. Fiscal 2026 revenue declined 4.6% to $17.32M, while net loss narrowed to $297K. The company expects $4.5M in Q1 2027 revenue. Gross profit rose 10% to $5.03M, and cash was $3.19M with zero debt.

Original reporting
Published Sep 30, 2026, 6:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 6:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Moving iMage Q4 Revenue Falls to $4.55M as Net Loss Reaches $296K — source image
Decision brief

The 30-second read

$MITQBearishMed
01

Why it matters

The earnings miss may trigger short‑term selling pressure, but the company's cash position and backlog offer some upside potential.

02

Market read

Micro‑cap earnings with modest revenue; limited market impact but relevant for traders tracking small‑cap volatility.

03

What to watch

Cash balance of $3.19M and zero debt provide runway; the order backlog of $458K could support near‑term sales.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Moving iMage Technologies (MITQ) released its Q4 2026 earnings, showing lower sales and a modest net loss.

Company-level read

Ticker impact

$MITQBearishHigh confidence
Context

Q4 net sales fell to $4.55M, down from $5.88M, and net loss widened to $296K.

Expected impact

likely downside as the market prices in weaker sales and higher loss

Evidence & confidence

The earnings release shows a revenue drop and a larger loss, which typically depresses a micro‑cap's price.

Market effects

Minimal; the company operates in a niche tech segment with limited broader impact.

None; the firm is US‑based and its size does not affect regional markets.

Low; micro‑cap earnings have little global significance.

Counterpoint

If the company can turn the revenue decline around in Q1, the stock may rebound despite the Q4 miss.

Key entities

  • Moving iMage Technologies

    Micro‑cap tech firm reporting Q4 results.

Related articles

$MITQMed

Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts…

MOVING iMAGE TECHNOLOGIES INC. (MITQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts Investor Call Today at 11am ET Fountain Valley, CA – September 28, 2026 – Moving iMage Technologies, Inc. (NYSE

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).